Cancer drug marches toward filing

Share this article:

Merrimack Pharmaceuticals said today that its candidate for metastatic pancreatic cancer, MM-398, in combination with 5-FU and leucovorin, met its primary endpoint and will be submitted to the FDA in 2014. The agency granted MM-398 an orphan drug designation for metastatic pancreatic cancer in 2011.

MM-398+5-FU+leucovorin saw an overall survival of 6.1 months, representing a 1.9-month improvement over the 4.2 months of survival demonstrated by a control arm of 5-FU+leucovorin alone. MM-398, on its own, did not demonstrate a statistically significant survival advantage, though.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.